High DNA-PKcs expression in tumours showed an adverse clinical outcome with poor ovarian cancer specific survival (p = 0.002) (Fig. 2d) and progression free survival (p = 0.0002) (Fig. 2e) compared with tumours that had low DNA-PKcs expression. Here, PRKDC is linked to ovarian cancer.